Academia.edu no longer supports Internet Explorer.
To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser.
Journal of Neuroscience Research
?-secretase as a target for the treatment of Alzheimer's disease2002 •
Medicinal Research Reviews
Boom in the development of non-peptidic β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease2009 •
β-Amyloid cleaving enzyme-1 (BACE1) has become a significant target for the therapy of Alzheimer's disease. After the discovery of the first non-peptidomimetic β-secretase inhibitors by Takeda Chemicals in 2001, several research teams focused on SAR development of these agents. The non-peptidic BACE1 inhibitors may potentially overcome the classical problems associated with the peptide structure of first generation, such as blood–brain barrier crossing, poor oral bioavailability and susceptibility to P-glycoprotein transport. In the past 6 years a boom in research of non-peptidic BACE1 inhibitors has disseminated findings over hundreds of publications and patents. The rapidly growing literature has been reviewed with particular emphasis on literature of pharmaceutical companies. © 2008 Wiley Periodicals, Inc. Med Res Rev, 29, No. 2, 295–338, 2009
Journal of Biological Chemistry
Characterization of Alzheimer's beta -Secretase Protein BACE. A PEPSIN FAMILY MEMBER WITH UNUSUAL PROPERTIES2000 •
2021 •
Analytical and Bioanalytical Chemistry
Beta-secretase as a target for Alzheimer’s disease drug discovery: an overview of in vitro methods for characterization of inhibitors2011 •
Bioorganic & Medicinal Chemistry Letters
Macrocyclic peptidomimetic β-secretase (BACE-1) inhibitors with activity in vivo2009 •
The number of individuals afflicted by Alzheimer’s disease (AD) worldwide is rapidly rising and we, as a society, are approaching a critical junction in the development of new therapeutics aimed at slowing or preventing the onset of this devastating neurodegenerative disease. The prevailing theory in the field pinpoints the amyloid β peptide (Aβ) as the causal agent of the disease and thus strategies that target the production, deposition, and clearance of Aβ in the brain continue to be at the forefront of therapeutic interventions. Aβ is produced through a series of proteolytic cleavage events, with β-secretase (BACE1) being the rate-limiting enzymatic activity needed to begin the liberation of the Aβ peptide from the larger amyloid precursor protein (APP). As such, BACE1 itself has become a prime therapeutic target for AD. Still, over ten years after its discovery, only a handful of compounds targeting BACE1 have reached clinical trial, indicating that complex challenges continue to persist. This short review will focus on the cellular and molecular characteristics of BACE1, its role in APP processing and in AD, and its potential as a therapeutic target for AD.
2015 •
Current Medicinal Chemistry
Interacting with γSecretase for Treating Alzheimer's Disease: From Inhibition to Modulation2011 •
Christianisme des origines. Mélanges en l’honneur du Professeur Paul-Hubert Poirier, éd. par Eric Crégheur , Julio Cesar D ias Chaves et Steve Johnston
2018 On the Pleasures and Perils of Codex Analysis2018 •
2020 •
Qualitative sociology review
Book review: “Researching children’s experiences” by Melissa Freeman and Sandra Mathison. The Guilford Press, New York 20092009 •
Beilstein Journal of Nanotechnology
A few-layer graphene/chlorin e6 hybrid nanomaterial and its application in photodynamic therapy against Candida albicans2020 •
공주출장샵&공주출장안마(카톡:nu222)공주출장오피ミ공주출장안마ミ공주출장만남추천ミ공주출장아가씨ミ공주출장마사지ミ공주출장업소ミ공주조건만남
공주출장샵&공주출장안마(카톡:nu222)공주출장오피ミ공주출장안마ミ공주출장만남추천ミ공주출장아가씨ミ공주출장마사지ミ공주출장업소ミ공주조건만남0 •
2016 •
Journal of Thoracic Oncology
P3.09-09 “Prevalence of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Carcinoma Lungs at a Cancer Center in Nepal”2018 •
2004 •
Mutation Research/Genetic Toxicology
Photobiological studies with dictamnine, a furoquinoline alkaloid1982 •